IJRR

International Journal of Research and Review

| Home | Current Issue | Archive | Instructions to Authors | Journals |

Review Article

Year: 2020 | Month: January | Volume: 7 | Issue: 1 | Pages: 70-75

Human Organic Transporter 1 (hOCT1) and Response to Imatinib in CML Patients: A Review

Namrata Bhutani

Senior Resident, Department Of Biochemistry, Vardhaman Mahavir Medical College & Safdarjung Hospital, New Delhi.

ABSTRACT

Most of the transporters with the ability to translocate organic cations across the plasma membrane belong to the solute carrier family 22A (general gene symbol SLC22A). SLC22A transporter group. It has been well established that the presence of genetic variants in genes encoding proteins involved in drug detoxification processes accounts for interindividual variability in drug response, and sometimes, this has severe consequences as regards drug toxicity and therapeutic efficacy. OCT1 is also expressed at the basolateral membrane of enterocytes, where, together with the combined transport activity of carriers localized at the apical membrane of these cells, it accounts for the secretion of organic cations toward the intestinal lumen. IM uptake is mediated by the hOCT1 protein encoded by the solute carrier 22 gene (SLC22A1). One third of CML patients treated with first line imatinib have suboptimal responses or treatment failures with increased risk for disease progression. This article reviews the role of human organic transporter 1 (hoct1) in eliciting a response to imatinib in CML patients.

Keywords: Human Organic Transporter 1 (hOCT1), Imatinib, CML Patients

[PDF Full Text]